Brigham

Newsweek and Statista Announce Second Annual America’s Best Fertility Clinics Ranking

Retrieved on: 
수요일, 4월 17, 2024
Statista, Mayo Clinic, Fertility, Hope, CDC, NYU Langone Health, Partnership, Brigham, Newsweek, Infertility, Accreditation, Reproductive medicine, Trust, Patient satisfaction, Birth control

NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Newsweek, the modern global digital news organization, in partnership with Statista, announced today the release of its America’s Best Fertility Clinics rankings.

Key Points: 
  • NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Newsweek, the modern global digital news organization, in partnership with Statista, announced today the release of its America’s Best Fertility Clinics rankings.
  • This is Newsweek’s second annual fertility clinics rankings, which includes 125 of America’s best clinics.
  • With the rise of fertility treatments in America, Newsweek’s rankings provide adults with information about the top clinics to help start or grow their families.
  • “The second annual America’s Best Fertility Clinics ranking has taken on a new meaning to Newsweek due to recent current events.

Canaan Adds Accomplished Executive and Scientist, Uwe Schoenbeck, Ph.D., Along with New Capital, to Bolster its Biopharma Investment Efforts

Retrieved on: 
수요일, 4월 17, 2024
Investment, Cell biology, Boehringer Ingelheim, News, Hospital, Abstract, Cardiology, CTI, WRDM, Partnership, Research, Brigham, Development, Cardiovascular Research, Therapy, Brigham and Women's Hospital, Senior, Science, Translation, Inflammatory bowel disease, Patient, Neurology, Acquisition, Initial public offering, General partnership, Metabolism, Harvard Medical School, Health, Assistant, Emerging, Biotechnology, Pharmaceutical industry

MENLO PARK, Calif., April 17, 2024 /PRNewswire/ -- Canaan, a venture capital firm that invests in entrepreneurs with visionary ideas, announced the addition of Uwe Schoenbeck, Ph.D., to its healthcare investment team as a new Venture Partner. Dr. Schoenbeck's impressive career has spanned more than 25 years in the life science and healthcare industry, as well as academia, providing him with an exceptional global network among leading research institutions, biotechnology and biopharmaceutical companies, and venture firms. He is highly regarded for his contributions in enabling and translating emerging science into breakthrough therapies, reaching from scientific collaborations, licensing, and acquisition deals to venture investing. In joining Canaan's healthcare investment team, Dr. Schoenbeck will help drive new investments and company creation from Canaan XIII, the firm's latest fund, by bringing in deep scientific and pharmaceutical perspectives, while also serving as a valuable resource to companies across the firm's existing biopharma portfolio. To this end, he has already facilitated his first investment as a member of the team, leading Canaan's participation in the recently announced $132 million Series B financing for Alterome Therapeutics and being named a member of the company's board of directors.

Key Points: 
  • Most recently, Dr. Schoenbeck served as Senior Vice President and Chief Scientific Officer Emerging Science & Innovation (ES&I) in Pfizer's Worldwide Research, Development & Medical (WRDM) division.
  • In leading ES&I, he worked to harness external breakthrough science, assets, and technologies by leveraging a broad range of partnering vehicles.
  • "It is not often that we have the opportunity to add someone of Uwe's caliber and track record to the Canaan investment team.
  • In additional news, Canaan today reported that it has expanded the size of its biopharma investment funds with the addition of more than $100 million in new capital.

Kaiser Permanente Bernard J. Tyson School of Medicine appoints Dr. John L. Dalrymple as new Dean and CEO

Retrieved on: 
화요일, 4월 16, 2024
Education, Harvard University, University, Reproductive biology, Moses Austin, Medical school, Hospital, Teaching, School, Health, Doctor of Philosophy, Brigham, Dell Medical School, MD Anderson Cancer Center, History, Medical education, OBGYN, Curriculum, Cone Health Women's Hospital, Dalrymple, Medicine, Ellen, Faculty, Harvard Medical School, Student, Massachusetts General Hospital, Nursing

PASADENA, Calif., April 16, 2024 /PRNewswire/ -- Today, the Board of Directors of the Kaiser Permanente Bernard J. Tyson School of Medicine (KPSOM) announced the appointment of physician, educator, and women's health expert John L. Dalrymple, MD, as the school's new Dean and CEO after an extensive national search. Dr. Dalrymple brings a wealth of academic leadership and teaching experience, respected expertise as a practicing physician, a proven record of delivering quality medical education and a commitment to advancing equitable healthcare. Dr. Dalrymple will begin his service as Dean and CEO on July 1, 2024.

Key Points: 
  • Dr. Dalrymple will begin his service as Dean and CEO on July 1, 2024.
  • Dr. Dalrymple currently serves as the senior associate dean for Medical Education at Harvard Medical School.
  • Together, we will ensure that our school remains at the forefront of innovation, equity, compassionate care, and excellence in medical education."
  • "I am deeply honored and immensely humbled to become part of this innovative, vibrant, and forward-thinking school and world-class healthcare organization.

Texas Department of Transportation Selects Woolpert for $3M Traffic Engineering and ITS Services Contract

Retrieved on: 
수요일, 3월 20, 2024
ITS, Bicycle, Transport, Pedestrian, Death, Brigham, BPAC, Accident, Injury, Lighting, Engineering, Fatality, Road

AUSTIN, Texas, March 20, 2024 /PRNewswire-PRWeb/ -- The Texas Department of Transportation has selected Woolpert to provide traffic engineering and intelligent transportation systems services under a five-year, $3 million contract supporting its Austin, Beaumont, and Fort Worth districts.

Key Points: 
  • AUSTIN, Texas, March 20, 2024 /PRNewswire-PRWeb/ -- The Texas Department of Transportation has selected Woolpert to provide traffic engineering and intelligent transportation systems services under a five-year, $3 million contract supporting its Austin, Beaumont, and Fort Worth districts.
  • Under this contract, we will be working closely with the Texas Department of Transportation to provide traffic safety analyses and other traffic engineering-related safety studies and designs to provide countermeasures for intersection crashes and other preventable accidents.
  • Woolpert will provide services supporting safety-related projects, including speed zone studies, traffic signal studies, traffic impact studies, safety analysis, traffic signal design, and ITS planning studies, design, and specifications development.
  • "Under this contract, we will be working closely with the Texas Department of Transportation to provide traffic safety analyses and other traffic engineering-related safety studies and designs to provide countermeasures for intersection crashes and other preventable accidents."

Point Foundation Welcomes New Board Members to Advance LGBTQ Empowerment

Retrieved on: 
목요일, 1월 18, 2024
Student, KPMG, LGBTQ, Brigham, Savage X Fenty, Internal medicine, Mentorship, Hospital, Point Foundation, Brigham and Women's Hospital, Management

LOS ANGELES, Jan. 18, 2024 /PRNewswire/ -- Point Foundation, the nation's leading scholarship-granting organization for LGBTQ college students, is thrilled to announce the appointment of new leaders to its boards.

Key Points: 
  • LOS ANGELES, Jan. 18, 2024 /PRNewswire/ -- Point Foundation, the nation's leading scholarship-granting organization for LGBTQ college students, is thrilled to announce the appointment of new leaders to its boards.
  • The new board members include:
    Carl Streed, Jr. – Associate Professor at the Boston University Chobanian & Avedisian School of Medicine.
  • Louis advocates for LGBTQ employees and improving the diversity, equity, and inclusion of KPMG as part of the LGBTQ employee resource group, pride@KPMG.
  • "As we navigate the political and social challenges to LGBTQ students seeking a post-secondary education in the years ahead of us, the insights and leadership of these new board members are essential to our mission of empowering LGBTQ students nationwide," said Jorge Valencia, executive director and CEO of Point Foundation.

Bionano Announces Presentation of OGM Utility Across Key Research Applications at the Association for Molecular Pathology Annual Meeting

Retrieved on: 
화요일, 11월 14, 2023
CNS, Research, Bone marrow, SAN, OGM, University, Hospital, Scalability, B-cell lymphoma, Expo Hall, Genomics, Second Level Address Translation, CD5, Laboratory, Neoplasm, Crocker, Ravindra and Smita Kolhe, Workflow, DSM-IV codes, SVS, Convention center, Greater Columbus Convention Center, Cancer, Mapping, Central nervous system, MD Anderson Cancer Center, AMP, Medical device, Vaccine, DRS, Adult, Brigham

AMP’s annual meeting brings together industry, medical, and academic professionals to discuss advances in molecular diagnostics.

Key Points: 
  • AMP’s annual meeting brings together industry, medical, and academic professionals to discuss advances in molecular diagnostics.
  • The presenters will share data on OGM’s performance in this research application as compared to traditional cytogenetic methods of analysis, including microarrays.
  • Ryall, Dubuc and Crocker presenting clinical research data generated using OGM across different types of hematological malignancies.
  • In addition, 19 posters featuring results from OGM applications in cytogenetic research will be presented at the conference.

Aspira Women’s Health Reports Third Quarter 2023 Financial Results

Retrieved on: 
월요일, 11월 13, 2023
Transfer, Assistant, Woman, Methodist Hospital, Research, Senior, Gynecologic Oncology (journal), Travel, University, Conference call, Risk, Gynaecology, Protein, MicroRNA, Dana–Farber Cancer Institute, Algorithm, Medical Affairs Bureau, Marketing, Metadata, AUP, COVID-19, Conference, Ovarian cancer, Harvard Medical School, University of Oxford, Brigham, CAB, Reproductive biology, Medical school, Aspira, Government, AACR, Hospital, Video game, Arms industry, Rare-earth element, Pharmaceutical industry, Birth control, Cryptocurrency, Obstetrics

AUSTIN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the three- and nine-month period ended September 30, 2023.

Key Points: 
  • “We are pleased to report another quarter of year-over-year growth, with revenues this quarter of $2.2 million.
  • The Company expects general and administrative expenses to remain flat for the fourth quarter of 2023.
  • Our cash balance this quarter benefited from the registered direct offering where we raised $4.7 million in gross proceeds.
  • The Company reiterates its operating cash utilization target for the second half of 2023 to between $6.0 million and $8.0 million.

Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023

Retrieved on: 
월요일, 11월 13, 2023
Disease, Esperion Therapeutics, Rash, Abdominal pain, AHA, Membrane protein, Patient, Bempedoic acid, PCSK9, CVD, Anemia, Angioedema, Rupture, Inflammation, Diet, Atherosclerosis, Safety, Incidence, FAHA, Mortality, Tablet, Health, Tendon rupture, Diarrhea, Harvard Medical School, Ezetimibe, Urinary tract infection, Fetus, Hypersensitivity, Arthralgia, Gout, American Heart Association, ESPR, Therapy, Sinusitis, Risk, Spasm, Constipation, MACE, Anaphylaxis, Pain, Moyamoya disease, Back pain, Upper respiratory tract infection, FACC, Flexner Report, CLEAR, Fatigue, Pregnancy, Kidney, Uric acid, MPH, ATP, Bronchitis, Hospital, Dietary supplement, Pharmaceutical industry, Vaccine, Common, Esperies, Brigham, Hyperuricemia, MD, Cholesterol

ANN ARBOR, Mich., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of results from a pre-specified, exploratory analysis of CLEAR Outcomes at the 2023 American Heart Association (AHA) Scientific Sessions. Results were also simultaneously published in Circulation which can be accessed here.

Key Points: 
  • “In the future, it can be anticipated that virtually all atherosclerosis patients will receive aggressive inflammation inhibition along with aggressive cholesterol reduction,” Ridker added.
  • In CLEAR Outcomes, patients who were randomized to bempedoic acid experienced a 21.6% reduction in hsCRP compared to placebo at 6 months.
  • At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data

Retrieved on: 
일요일, 11월 12, 2023
AHA, Patient, MACE, Heart failure, American Heart Association, HF, Hospital, Pharmaceutical industry, Boston, Brigham

THE WOODLANDS, Texas, Nov. 12, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a post hoc analysis of clinical data from the SCORED trial demonstrated that clinical benefit from INPEFA® (sotagliflozin) use in heart failure (HF) and major adverse cardiovascular events (MACE) related outcomes was observed as early as approximately three months in patients at high risk for cardiovascular events. The data were shared in an oral presentation by Rahul Aggarwal, M.D., Brigham and Women’s Hospital, Boston, Massachusetts, at the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia, Pennsylvania.

Key Points: 
  • The data were shared in an oral presentation by Rahul Aggarwal, M.D., Brigham and Women’s Hospital, Boston, Massachusetts, at the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia, Pennsylvania.
  • The goal of the analysis was to evaluate the time to clinical benefit for HF and MACE related outcomes in patients at high risk for cardiovascular events and treated with sotagliflozin.
  • A statistically significant sustained reduction in the primary endpoint was seen at 95 days after randomization (HR=0.70; 95% CI: 0.50, 0.98).
  • A statistically significant sustained reduction in MACE was seen at 94 days after randomization (HR=0.69; 95% CI: 0.47, 0.99).

CinFina Pharma, a CinRx Portfolio Company, Introduces Scientific Advisory Board with Deep Metabolic Expertise

Retrieved on: 
목요일, 12월 14, 2023
Biotechnology, Pharmaceutical, Health, CNS, DPP, Peptide, Patient, MOVE, Investigational New Drug, Human, Diabetes, Bangladesh Technical Education Board, Pharma, Inflammation, Energy, Diet, Safety, Treatment, IND, Cardiovascular disease, Division, Wellness, Harvard Medical School, Brigham, PYY, Overweight, Society, Physician, Obesity medicine, Adipose tissue, Medicine, FACP, DSM-IV codes, SAB, Pharmacokinetics, Defense, Peptide YY, Identification, Weill Cornell Medicine, Research, Nutritional science, The New York Times, Metabolism, DASH, NIH, Weight loss, Pharmaceutical industry, Soft drink, Dietary supplement, Obesity

CinFina Pharma, CinRx Pharma’s portfolio company dedicated to expanding treatment options for obesity and metabolic diseases, today announced the scientific advisory board (SAB) members for the company’s multi-asset pipeline.

Key Points: 
  • CinFina Pharma, CinRx Pharma’s portfolio company dedicated to expanding treatment options for obesity and metabolic diseases, today announced the scientific advisory board (SAB) members for the company’s multi-asset pipeline.
  • The members of CinFina’s SAB include renowned metabolic and obesity academic researchers and expert clinicians.
  • Louis Aronne, M.D., FACP is a professor of metabolic research at Weill-Cornell Medical College, and director of the Center for Weight Management and Metabolic Clinical Research.
  • His research activities focus on understanding the mechanisms responsible for metabolic abnormalities associated with obesity and the therapeutic effects of weight loss.